Jefferies Group Comments on Repligen Corporation’s FY2020 Earnings (RGEN)
Repligen Corporation (NASDAQ:RGEN) – Investment analysts at Jefferies Group issued their FY2020 earnings per share (EPS) estimates for shares of Repligen Corporation in a report released on Tuesday. Jefferies Group analyst B. Couillard anticipates that the biotechnology company will post earnings per share of $1.12 for the year. Jefferies Group has a “Hold” rating and a $40.00 price objective on the stock.
RGEN has been the topic of a number of other reports. Zacks Investment Research upgraded shares of Repligen Corporation from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a research note on Saturday, August 12th. BidaskClub lowered shares of Repligen Corporation from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, June 14th. Stephens reiterated an “overweight” rating and set a $50.00 price target on shares of Repligen Corporation in a research note on Tuesday, September 26th. William Blair started coverage on shares of Repligen Corporation in a research note on Friday, July 21st. They set an “outperform” rating on the stock. Finally, TheStreet upgraded shares of Repligen Corporation from a “c+” rating to a “b-” rating in a research note on Friday, August 11th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Repligen Corporation has an average rating of “Buy” and a consensus target price of $45.40.
Repligen Corporation (NASDAQ:RGEN) traded down 0.71% during midday trading on Wednesday, hitting $38.00. The stock had a trading volume of 166,852 shares. The stock has a 50 day moving average of $41.79 and a 200 day moving average of $39.54. Repligen Corporation has a 12 month low of $26.16 and a 12 month high of $46.81. The stock has a market cap of $1.42 billion, a price-to-earnings ratio of 74.36 and a beta of 1.18.
Repligen Corporation (NASDAQ:RGEN) last posted its earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 EPS for the quarter, beating the Zacks’ consensus estimate of $0.15 by $0.05. Repligen Corporation had a return on equity of 9.90% and a net margin of 15.61%. The firm had revenue of $32.40 million for the quarter, compared to analysts’ expectations of $31.72 million. During the same period last year, the firm earned $0.16 EPS. The company’s quarterly revenue was up 11.0% on a year-over-year basis.
Institutional investors and hedge funds have recently modified their holdings of the business. Quantbot Technologies LP acquired a new position in Repligen Corporation during the second quarter worth about $120,000. Ameritas Investment Partners Inc. acquired a new position in Repligen Corporation during the first quarter worth about $103,000. Oppenheimer Asset Management Inc. acquired a new position in Repligen Corporation during the second quarter worth about $123,000. Victory Capital Management Inc. grew its position in Repligen Corporation by 76.6% during the first quarter. Victory Capital Management Inc. now owns 3,400 shares of the biotechnology company’s stock worth $120,000 after buying an additional 1,475 shares during the period. Finally, JPMorgan Chase & Co. grew its position in Repligen Corporation by 31.9% during the first quarter. JPMorgan Chase & Co. now owns 3,755 shares of the biotechnology company’s stock worth $133,000 after buying an additional 908 shares during the period. Institutional investors own 97.91% of the company’s stock.
About Repligen Corporation
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Stock Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related stocks with our FREE daily email newsletter.